Contact

Background

Background

Neuroimmune diseases include multiple sclerosis (MS), neuromyelitis optica spectrum disease (NMOSD), autoimmune encephalitis (AE), Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), myasthenia gravis (MG), Guillain-Barre syndrome (GBS), inflammatory peripheral neurological diseases, etc. The cause of these diseases is unclear. The pathological mechanism is that the T cells and B cells that mediate the immune system mistakenly attack the central or peripheral nerve tissue and receptors in neuromuscular dissemination as an external antigen, resulting in immune-mediated pathological damage and nerve or muscles and other tissues. Neuroimmune diseases are the main reason for young adult disability. Clinical manifestations are complex and diverse. The choice of treatment and adjustment requires experienced experts. Early and correct diagnosis, monitoring of disease progression, and drug efficacy mainly depend on the detection of fluid biomarkers, including antigen, antibody, and trace nerve tissue protein.

Originate

In 2010, under the leadership of Professors Fu-Dong Shi and Li Yang, the Neurology Department of Tianjin Medical University General Hospital established a specialized outpatient and ward for the diagnosis, treatment, and long-term management of neuroimmune diseases. It took the lead in using disease-modifying drugs in China and accumulated rich experience. In 2018, Beijing Tiantan Hospital and China National Clinical Research Center for Neurological Diseases were relocated to Fengtai district of Beijing. Professor Fu-Dong Shi integrated the neuroimmunology teams and streamlined clinical service and research both Tianjin Medical University General Hospital and Beijing Tiantan Hospital, thus laid foundation for Jing-Jin Center for Neuroinflammation, expanding the patient's service to national and international patients.

Tianjin New Terrain Biotechnology Co., Ltd. (New Terrain), born in 2018, is a product of the expanding clinical service demand from Jing-Jin Center for Neuroinflammation and national initiatives for technology independence.

Honours

2023
生物医药领域三等奖
授予单位

天津市创新创业大赛组委会

2021
国家级科技型中小企业
授予单位

天津市科学技术局

2021
天津雏鹰企业
授予单位

天津市科学技术局

Obtained patents

用于检测重症肌无力相关抗体的组合物、试剂盒及应用
专利号

ZL 2022 1 0072137.2

申请日期

2022年01月21日

检测甲酰肽或甲酰肽受体-1 配体含量的方法及应用
专利号

ZL 2020 1 0322743.6

申请日期

2020年04月22日

一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
专利号

ZL 2019 1 1309884.8

申请日期

2019年12月18日

防止或减轻rtPA用药后出血转化的方法和药物
专利号

ZL 2019 1 0335185.4

申请日期

2019年04月24日

环孢菌素H环糊精及其用途
专利号

ZL 2019 1 0119243.X

申请日期

2019年02月18日

一种载玻片及样品处理装置
专利号

ZL 2020 2 0521246.4

申请日期

2020年04月10日

天津天海新域生物科技有限公司
核定使用商品/服务项目

国际分类 5

注册日期

2021年02月14日

一种同时检测中枢脱髓鞘自身抗体AQP4、MOG和MBP的方法
申请日期

2020年01月09日

一种用于检测AQP4抗体的细胞爬片及应用
申请日期

2019年12月04日

Participation in academic conferences

Based on the innovations of our team for more than ten years, we are committed to

Developing laboratory diagnostic reagents for neuroinflammatory diseases, and expanding the neurological biomarker detection array for diagnosis, progress, curative effect prediction;

Screening new fluid biomarkers for early diagnosis, progress and prognosis evaluation of neurodegenerative diseases such as cognitive disorders and movement disorders;

Pre-clinical and clinical trial services;

Develop new immunomodulatory drugs for single or combinational treatment of neurological diseases.

In the three years since the establishment of New Terrain, the R&D department has been determined to forge ahead, the technology has been continuously upgraded, and the product pipeline and intellectual property rights have been enriched.

At present, the company has reached strategic cooperation with KingMed Diagnostics, the largest third-party medical laboratory in China, and has gradually formed an integrated model of national laboratory diagnosis and clinical information services.

Our Team